What Is NanoNeuroscience?

An established scientific field at the intersection of nanotechnology and neuroscience.

Nanoneuroscience applies nanoscale science and engineering to the study, diagnosis and treatment of the nervous system.

Nanoneuroscience is the application of nanoscale science and engineering to the nervous system - bringing together neuroscience, nanotechnology, medicine, materials science and biomedical engineering.

Research spans nanoscale drug delivery, blood-brain barrier transport, brain imaging, nanomaterials, neural interfaces, and approaches to diagnosing and treating neurological disease.

This isn't a term assembled for a domain listing. Nanoneuroscience is already used in peer-reviewed literature, specialist textbooks, and active research programmes.

A Real Scientific Field, Not a Coined Phrase

The terminology has been established for well over a decade. Published literature has explicitly treated "nanoneuroscience" as a distinct discipline, and the field has its own specialist reference work: The Textbook of Nanoneuroscience and Nanoneurosurgery, first published in 2013, now in a second Springer edition.

The textbook's coverage spans:

• Neurosurgery, neurology, neuroscience and neuroradiology
• Drug development and delivery
• Brain imaging
• Nanobiotechnology and nanomaterials
• Neural disease management

The Society for Brain Mapping and Therapeutics describes the original edition as drawing on more than 120 researchers and 3,000 references.

Why the Brain Is a Nanotechnology Problem

One of the central challenges in neurological medicine is delivery: getting therapeutic compounds to the right place. The blood-brain barrier protects the central nervous system — and makes drug delivery exceptionally difficult.

Research into nanoscale carriers explores whether therapeutic molecules can be transported across this barrier more effectively than with conventional delivery methods. This remains active, ongoing research, not a solved problem.

Where the Research Is Going

Drug Delivery — nanocarriers, liposomes, micelles and dendrimers are being investigated to control where, when and how therapeutic molecules reach neurological targets.

Brain Imaging — nanoscale technologies are being explored for more precise molecular-level detection, not simply higher-resolution pictures.

Neural Interfaces — nanostructured materials are being researched for neural electrodes and biosensors, feeding into the broader development of brain-machine interfaces.

Nano-Neurosurgery — the field extends into nanoparticle-guided surgical and neuromodulation approaches.

Neurological Disease — research spans stroke, Parkinson's, Alzheimer's, epilepsy and brain tumours. These are active research areas, not evidence of approved treatments.

From Research to Commercialisation

The terminology is beginning to move beyond pure research. As nanomedicine and neurotechnology mature into commercial fields, the language developed within nanoneuroscience is increasingly the vocabulary those companies use to describe what they do.

The Category Is Still Developing

Nanoneuroscience is not yet a mature commercial industry. There's no single "nanoneuroscience market" comparable to established pharmaceutical sectors. The science has passed the stages that usually come first - a recognised term, dedicated literature, a specialist textbook, active research, and now the beginnings of commercial activity. Where it goes commercially from here is genuinely open.

The Market Is Accelerating Now, Not Later

The 2013 edition of The Textbook of Nanoneuroscience and Nanoneurosurgery projected that nanoneuroscience, nanoneurosurgery and nanobioelectronics could meaningfully transform neurological medicine over a 10–20 year horizon.

More than a decade into that window, the broader nanomedicine market is growing quickly. Multiple independent market research firms report the global nanomedicine market at roughly $375–435 billion in 2025–2026, projected to reach $724–786 billion by 2030–2035 at a 12–16% compound annual growth rate. The nanomedicine drug delivery segment specifically is forecast to grow from $142.7 billion in 2026 to $252.69 billion by 2030.

Growth is being driven in part by a trend directly relevant to this field: increasing integration of AI into nanomedicine research and formulation design. The same technological shift powering advances across AI-driven drug discovery is now being applied to the nanoscale delivery and diagnostic challenges nanoneuroscience was built to address.

Commercial capital is following. In September 2025, NanoMedicine Revolution raised an $870 million Series D funding round, reaching a $13.1 billion valuation - one indication of the scale of investor confidence now flowing into this broader category.

This isn't a field whose moment has passed. By most available market measures, it's accelerating.

Why the Name Matters

Scientific fields typically acquire their own terminology long before their commercial markets mature. NanoNeuroscience.com is the exact, singular form of a field that has already passed several of those early stages - genuine academic depth, without yet a single dominant commercial category.

Potential applications include a research platform, a neurotechnology venture's identity, a nanomedicine company, a specialist publication, or an industry conference and community hub.

The OOODE View

This isn't a claim that nanoneuroscience is guaranteed to become a large commercial category. The case is simpler: the field already exists, the terminology is established, the literature is substantial, and commercial language is beginning to form around it. That's a precise name for a field that already exists - not a speculative word.

Domain NanoNeuroscience.com

available at OOODE: $75,000

Valuation range: $40,000–$125,000

Available for acquisition through OOODE.